133 related articles for article (PubMed ID: 12974799)
1. HLA class I expression in bladder carcinomas.
Cabrera T; Pedrajas G; Cozar JM; Garrido A; Vicente J; Tallada M; Garrido F
Tissue Antigens; 2003 Oct; 62(4):324-7. PubMed ID: 12974799
[TBL] [Abstract][Full Text] [Related]
2. High frequency of altered HLA class I phenotypes in laryngeal carcinomas.
Cabrera T; Salinero J; Fernandez MA; Garrido A; Esquivias J; Garrido F
Hum Immunol; 2000 May; 61(5):499-506. PubMed ID: 10773352
[TBL] [Abstract][Full Text] [Related]
3. LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas.
Maleno I; Romero JM; Cabrera T; Paco L; Aptsiauri N; Cozar JM; Tallada M; López-Nevot MA; Garrido F
Immunogenetics; 2006 Jul; 58(7):503-10. PubMed ID: 16705407
[TBL] [Abstract][Full Text] [Related]
4. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.
Maleno I; López-Nevot MA; Cabrera T; Salinero J; Garrido F
Cancer Immunol Immunother; 2002 Sep; 51(7):389-96. PubMed ID: 12192539
[TBL] [Abstract][Full Text] [Related]
5. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas.
Cabrera T; Collado A; Fernandez MA; Ferron A; Sancho J; Ruiz-Cabello F; Garrido F
Tissue Antigens; 1998 Aug; 52(2):114-23. PubMed ID: 9756399
[TBL] [Abstract][Full Text] [Related]
6. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
[TBL] [Abstract][Full Text] [Related]
7. Different mechanisms can lead to the same altered HLA class I phenotype in tumors.
Rodriguez T; Aptsiauri N; Méndez R; Jimenez P; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2007 Apr; 69 Suppl 1():259-63. PubMed ID: 17445215
[TBL] [Abstract][Full Text] [Related]
8. Involvement of HLA class I molecules in the immune escape of urologic tumors.
Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
[TBL] [Abstract][Full Text] [Related]
9. HLA-G and MIC expression in tumors and their role in anti-tumor immunity.
Seliger B; Abken H; Ferrone S
Trends Immunol; 2003 Feb; 24(2):82-7. PubMed ID: 12547505
[TBL] [Abstract][Full Text] [Related]
10. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
11. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers.
de Miranda NF; Nielsen M; Pereira D; van Puijenbroek M; Vasen HF; Hes FJ; van Wezel T; Morreau H
J Pathol; 2009 Sep; 219(1):69-76. PubMed ID: 19462419
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific upregulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma.
Gan LH; Huang LF; Zhang X; Lin A; Xu DP; Wang Q; Wang TJ; Yan WH
Hum Immunol; 2010 Sep; 71(9):899-904. PubMed ID: 20600448
[TBL] [Abstract][Full Text] [Related]
13. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas.
Nie Y; Yang G; Song Y; Zhao X; So C; Liao J; Wang LD; Yang CS
Carcinogenesis; 2001 Oct; 22(10):1615-23. PubMed ID: 11577000
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.
Carretero R; Cabrera T; Gil H; Saenz-Lopez P; Maleno I; Aptsiauri N; Cozar JM; Garrido F
Int J Cancer; 2011 Aug; 129(4):839-46. PubMed ID: 20957629
[TBL] [Abstract][Full Text] [Related]
15. HLA class I molecules in the placenta: which ones, where and what for? A workshop report.
Le Bouteiller P; Sargent IL
Placenta; 2000; 21 Suppl A():S93-6. PubMed ID: 10831131
[No Abstract] [Full Text] [Related]
16. Loss of heterozygosity at 6p21 and HLA class I expression in esophageal squamous cell carcinomas in China.
Zhao X; Sun Q; Tian H; Cong B; Jiang X; Peng C
Asian Pac J Cancer Prev; 2011; 12(10):2741-5. PubMed ID: 22320985
[TBL] [Abstract][Full Text] [Related]
17. Do nonhuman primates comprise appropriate experimental models for studying the function of human leukocyte antigen-G?
Langat DK; Hunt JS
Biol Reprod; 2002 Nov; 67(5):1367-74. PubMed ID: 12390864
[TBL] [Abstract][Full Text] [Related]
18. HLA class I expression on the materno-fetal interface.
Hammer A; Hutter H; Dohr G
Am J Reprod Immunol; 1997 Sep; 38(3):150-7. PubMed ID: 9325485
[TBL] [Abstract][Full Text] [Related]
19. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival.
Levin I; Klein T; Goldstein J; Kuperman O; Kanetti J; Klein B
Cancer; 1991 Dec; 68(12):2591-4. PubMed ID: 1933807
[TBL] [Abstract][Full Text] [Related]
20. High frequency of HLA-B44 allelic losses in human solid tumors.
Cabrera T; Maleno I; Lopez-Nevot MA; Redondo M; Fernandez MA; Collado A; Garrido F
Hum Immunol; 2003 Oct; 64(10):941-50. PubMed ID: 14522091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
